Future of Drug Discovery: The Synergy of Edge Computing, Internet of Medical Things, and Deep Learning

Mohammad (Behdad) Jamshidi (), Omid Moztarzadeh, Alireza Jamshidi, Ahmed Abdelgawad, Ayman S. El-Baz and Lukas Hauer
Additional contact information
Mohammad (Behdad) Jamshidi: Faculty of Electrical Engineering, University of West Bohemia, Univerzitní 22, 30614 Pilsen, Czech Republic
Omid Moztarzadeh: Department of Stomatology, University Hospital Pilsen, Faculty of Medicine in Pilsen, Charles University, 32300 Pilsen, Czech Republic
Alireza Jamshidi: Dentistry School, Babol University of Medical Sciences, Babol 47176-47745, Iran
Ahmed Abdelgawad: College of Science and Engineering, Central Michigan University, Mount Pleasant, MI 48859, USA
Ayman S. El-Baz: Department of Bioengineering, University of Louisville, Louisville, KY 40292, USA
Lukas Hauer: Department of Stomatology, University Hospital Pilsen, Faculty of Medicine in Pilsen, Charles University, 32300 Pilsen, Czech Republic

Future Internet, 2023, vol. 15, issue 4, 1-15

Abstract: The global spread of COVID-19 highlights the urgency of quickly finding drugs and vaccines and suggests that similar challenges will arise in the future. This underscores the need for ongoing efforts to overcome the obstacles involved in the development of potential treatments. Although some progress has been made in the use of Artificial Intelligence (AI) in drug discovery, virologists, pharmaceutical companies, and investors seek more long-term solutions and greater investment in emerging technologies. One potential solution to aid in the drug-development process is to combine the capabilities of the Internet of Medical Things (IoMT), edge computing (EC), and deep learning (DL). Some practical frameworks and techniques utilizing EC, IoMT, and DL have been proposed for the monitoring and tracking of infected individuals or high-risk areas. However, these technologies have not been widely utilized in drug clinical trials. Given the time-consuming nature of traditional drug- and vaccine-development methods, there is a need for a new AI-based platform that can revolutionize the industry. One approach involves utilizing smartphones equipped with medical sensors to collect and transmit real-time physiological and healthcare information on clinical-trial participants to the nearest edge nodes (EN). This allows the verification of a vast amount of medical data for a large number of individuals in a short time frame, without the restrictions of latency, bandwidth, or security constraints. The collected information can be monitored by physicians and researchers to assess a vaccine’s performance.

Keywords: artificial intelligence; big data; deep learning; drug discovery; edge computing; internet of things; internet of medical things; natural language processing (search for similar items in EconPapers)
JEL-codes: O3 (search for similar items in EconPapers)
Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1999-5903/15/4/142/pdf (application/pdf)
https://www.mdpi.com/1999-5903/15/4/142/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jftint:v:15:y:2023:i:4:p:142-:d:1118134

Access Statistics for this article

Future Internet is currently edited by Ms. Grace You

More articles in Future Internet from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().